semaglutide and masld in — the story is evolving. A stimulating discussion on how GLP-1 receptor agonists are reshaping the management of MASLD/MASH. Beyond consistent weight loss MASH resolution, emerging phase-3 data What is metabolic dysfunction–associated steatotic

The Wegovy label notes increased hypoglycemia risk when semaglutide is used concomitantly with insulin or an insulin secretagogue, and states that use in type 1 diabetes or in combination with insulin has not been evaluated

These changes collectively contribute to a breakdown in immune homeostasis, the Treg/Th17 balance shifts toward a pro-inflammatory state, Tfh cells promote B cell hyperactivation and autoantibody production, and mTOR pathway activation enhances glycolytic metabolism and inflammatory cytokine release in immune cells, ultimately leading to multitissue injury

If you already experience hormonally driven acne, vitamin B12 may add to this imbalance

Serotonin syndrome following methylene blue administration for vasoplegic syndrome

MAPK phosphorylation of connexin 43 promotes binding of cyclin e and smooth muscle cell proliferation